文献速递外周动脉疾病内脏/肾动脉与血管畸形

二氧化碳血管造影作为血管内手术唯一对比剂的应用

Carbon Dioxide Angiography as a Sole Contrast Modality in Endovascular Procedures.
PubMed 文献 · Ann Vasc Surg · 2026-08-10

该回顾性研究纳入28例仅用二氧化碳血管造影完成血管内手术的患者,技术成功率92.86%(26/28),术后24小时和1个月血清肌酐与术前无显著差异(P>0.05),原有肾功能不全者肌酐亦无显著变化(P>0.05),2例肾动脉支架需补充碘对比剂,无二氧化碳相关并发症。

要点

  • 二氧化碳血管造影作为唯一对比剂的技术成功率为92.86%(26/28)。
  • 术后24小时和1个月血清肌酐与术前无显著差异(P>0.05)。
  • 无二氧化碳相关并发症发生。

核心结论

  • 在小样本回顾性设计的局限下,二氧化碳血管造影对特定血管内手术是可行且可接受安全的影像替代方法,尤其适用于有碘对比剂禁忌证的患者。

研究设计与样本

  • 回顾性收集2021年4月至2025年12月28例仅用二氧化碳血管造影完成各类血管内手术患者的临床数据。

主要发现

  • 技术成功率为92.86%(26/28例)。
  • 术后24小时血清肌酐112.85 μmol/L(IQR 63.52-357.57)和1个月104.70 μmol/L(IQR 65.35-356.62)与术前105.55 μmol/L(IQR 64.15-349.23)无统计学显著差异(P>0.05)。
  • 13例原有肾功能不全者术后24小时平均血清肌酐358.70 ± 94.53 μmol/L和1个月353.68 ± 90.10 μmol/L与术前平均355.37 ± 91.64 μmol/L无显著差异(P>0.05)。
  • 2例肾动脉支架因图像质量欠佳分别补充10 mL和15 mL碘对比剂。
  • 任何患者术中或术后均未发生二氧化碳相关并发症。

临床怎么用

  • 对于有碘对比剂禁忌证(如肾功能不全或过敏)的患者,可考虑将二氧化碳血管造影作为血管内手术的唯一对比剂。

局限性

  • 小样本回顾性设计,初步发现需更大规模前瞻性多中心研究确认后方可推荐更广泛临床应用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Iodinated contrast medium (ICM) carries risks of allergic reaction and post contrast acute kidney injury. Carbon dioxide (CO2) angiography offers a potential alternative for patients with renal insufficiency or ICM allergy. Although extensive international studies have demonstrated the efficacy of CO2 angiography, data on local populations remain limited. To provide region-specific data, we evaluated the accuracy and safety of CO2 as the sole contrast modality in regional endovascular procedures. METHODS: Clinical data of 28 patients who underwent various endovascular procedures using CO2 angiography alone from April 2021 to December 2025 were retrospectively collected and analyzed. The primary end point was technical success. Secondary end points included postoperative renal function impairment and the incidence of complications. RESULTS: The technical success rate for procedures performed with CO2 angiography alone was 92.86% (26/28 cases). Serum creatinine (sCr) levels at 24 hours and 1 month postoperatively [112.85 μmol/L (interquartile range [IQR], 63.52-357.57) and 104.70 μmol/L (IQR, 65.35-356.62), respectively] showed no statistically significant difference compared to preoperative levels [105.55 μmol/L (IQR, 64.15-349.23)] (P > 0.05). In the 13 patients with preexisting renal insufficiency, mean sCr at 24 hours (358.70 ± 94.53 μmol/L) and 1 month (353.68 ± 90.10 μmol/L) also did not differ significantly from the preoperative mean (355.37 ± 91.64 μmol/L) (P > 0.05). Two patients undergoing renal artery stenting required adjunctive ICM (10 mL and 15 mL, respectively) due to suboptimal image quality. No CO2-related complications occurred in any patient during or after the operation. CONCLUSION: Within the constraints of a small retrospective design, CO2 angiography appears to be a feasible and acceptably safe imaging alternative for specific endovascular procedures, particularly in patients with contraindications to ICM. These preliminary findings require confirmation through larger, prospective, multicenter investigations before broader clinical adoption can be recommended.

来源:Ann Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Sun Y, Shen Y, Wang Y, et al. Carbon Dioxide Angiography as a Sole Contrast Modality in Endovascular Procedures. Ann Vasc Surg. 2026. PMID: 42575267. doi:10.1016/j.avsg.2026.07.046

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。